$7.88
1.62% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US2825591033
Symbol
ETNB
Sector
Industry

89bio Inc Stock price

$7.88
-1.26 13.79% 1M
+0.34 4.51% 6M
-3.29 29.45% YTD
-3.23 29.07% 1Y
-5.62 41.63% 3Y
-16.77 68.03% 5Y
-12.92 62.12% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.13 1.62%
ISIN
US2825591033
Symbol
ETNB
Sector
Industry

Key metrics

Market capitalization $926.55m
Enterprise Value $540.35m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.21
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-303.86m
Free Cash Flow (TTM) Free Cash Flow $-280.54m
Cash position $423.77m
EPS (TTM) EPS $-2.91
P/E forward negative
Short interest 6.25%
Show more

Is 89bio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

89bio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a 89bio Inc forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a 89bio Inc forecast:

Buy
75%
Hold
25%

Financial data from 89bio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.05 0.05
71% 71%
-
-0.05 -0.05
71% 71%
-
- Selling and Administrative Expenses 36 36
33% 33%
-
- Research and Development Expense 267 267
148% 148%
-
-304 -304
125% 125%
-
- Depreciation and Amortization 0.05 0.05
71% 71%
-
EBIT (Operating Income) EBIT -304 -304
124% 124%
-
Net Profit -289 -289
128% 128%
-

In millions USD.

Don't miss a Thing! We will send you all news about 89bio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

89bio Inc Stock News

Neutral
GlobeNewsWire
9 days ago
SAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified ...
Neutral
GlobeNewsWire
29 days ago
SAN FRANCISCO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified ...
Neutral
GlobeNewsWire
about one month ago
New post-hoc analyses reinforce pegozafermin's potential anti-fibrotic effects and the potential utility of non-invasive tests which correlate to histological endpoints New post-hoc analyses reinforce pegozafermin's potential anti-fibrotic effects and the potential utility of non-invasive tests which correlate to histological endpoints
More 89bio Inc News

Company Profile

89bio, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases. The company was founded on January 01, 2018 and is headquartered in San Francisco, CA.

Head office United States
CEO Rohan Palekar
Employees 70
Founded 2018
Website www.89bio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today